- Home
- NVAX vs KRP Comparison
NVAX vs KRP Comparison
Compare NVAX & KRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- KRP
- Stock Information
- Founded
- NVAX 1987
- KRP 2013
- Country
- NVAX United States
- KRP United States
- Employees
- NVAX N/A
- KRP N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- KRP Oil & Gas Production
- Sector
- NVAX Health Care
- KRP Energy
- Exchange
- NVAX Nasdaq
- KRP Nasdaq
- Market Cap
- NVAX 1.3B
- KRP 1.1B
- IPO Year
- NVAX 1995
- KRP 2017
- Fundamental
- Price
- NVAX $7.84
- KRP $13.98
- Analyst Decision
- NVAX Hold
- KRP Hold
- Analyst Count
- NVAX 6
- KRP 5
- Target Price
- NVAX $15.00
- KRP $17.40
- AVG Volume (30 Days)
- NVAX 8.6M
- KRP 478.7K
- Earning Date
- NVAX 08-06-2025
- KRP 08-07-2025
- Dividend Yield
- NVAX N/A
- KRP 12.32%
- EPS Growth
- NVAX N/A
- KRP N/A
- EPS
- NVAX 2.54
- KRP N/A
- Revenue
- NVAX $1,078,718,000.00
- KRP $312,566,668.00
- Revenue This Year
- NVAX $52.02
- KRP $11.39
- Revenue Next Year
- NVAX N/A
- KRP $3.39
- P/E Ratio
- NVAX $3.08
- KRP N/A
- Revenue Growth
- NVAX 9.22
- KRP N/A
- 52 Week Low
- NVAX $5.01
- KRP $10.98
- 52 Week High
- NVAX $15.22
- KRP $16.99
- Technical
- Relative Strength Index (RSI)
- NVAX 48.26
- KRP 43.90
- Support Level
- NVAX $7.57
- KRP $13.46
- Resistance Level
- NVAX $10.64
- KRP $14.55
- Average True Range (ATR)
- NVAX 0.72
- KRP 0.27
- MACD
- NVAX -0.07
- KRP -0.12
- Stochastic Oscillator
- NVAX 29.47
- KRP 31.33
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.